Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorZhao Jun
About this trial
This study aims to investigate the impact of immunotherapy on the immune status of tumor microenvironment and peripheral blood of chest cancer patients. To do so, the investigators plan to collect tumor tissue and peripheral blood samples before and after immunotherapy, and use single-cell RNA sequencing, Multiplex immunohistochemistry, and flow cytometry. The investigators will analyze changes in the proportion of cancer cell-specific T-cell subpopulations related to treatment response before and after therapy, and seek biological markers that can predict the efficacy of immunotherapy.
Eligibility criteria
Qualifiers
Patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive PD-1/PD-L1 antibody immunotherapy;
Age between 18 and 80 years old;
ECOG PS score of 0 or 1;
Adequate organ and bone marrow function;
Disqualifiers
Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C.
Patients with tumor emergencies that require immediate treatment.
Poor vascular conditions.
Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy.
Trial design
Treatments tested in this trial
- In vitro stimulation of Pbmc with tumor antigen nanoparticles
Treatment groups
No treatment groups listed
Sponsors and collaborators
Zhao Jun
Lead sponsor
The First Affiliated Hospital of Soochow University
Sponsor institution
Source ClinicalTrials.gov